1318P - Phase II study of 2 dosing regimens of cemiplimab, a human monoclonal anti–PD-1, in metastatic cutaneous squamous cell carcinoma (mCSCC)

D Rischin, A.M Lim + Show 17 more

Open Access

https://doi.org/10.1093/annonc/mdz255.007

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Oct 1, 2019
Citations: 5	License type: publisher-specific-oa

Affiliation: Peter MacCallum Cancer Centre, Sir Charles Gairdner Hospital, Brigham and Women's Hospital, Moffitt Cancer Center, Royal Brisbane and Women's Hospital, Essen University Hospital, Memorial Sloan Kettering Cancer Center, Stanford University, University of Lübeck, University Hospital Schleswig-Holstein, Charité - Universitätsmedizin Berlin, Universitätsmedizin Göttingen, The University of Texas MD Anderson Cancer Center, New York University Langone Medical Center, Cleveland Clinic, Regeneron (United States), Royal North Shore Hospital

#Research Grant #Regeneron Pharmaceuticals + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

1318P - Phase II study of 2 dosing regimens of cemiplimab, a human monoclonal anti–PD-1, in metastatic cutaneous squamous cell carcinoma (mCSCC)

Full Text

Published version (

Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Annals of oncology : official journal of the European Society for Medical Oncology

Paper Title

Journal

Date

Author

View more papers

Translate this paper in your preferred language
Listen to the abstract of this paper

Save
Share
Export